Business highlights in Q1 2022
- On January 20th the initiation of dosing in the IPTN2021 program Phase 1 to assess pain reducing effects in healthy volunteers was announced.
- On March 22nd it was announced that the inclusion of test subjects in the IPTN2021 Phase 1 study had been completed.
Business highlights after this reporting period
- On April 5th the Company announced that it has signed an option agreement for a Phase 2/3 ready drug asset for an undisclosed pain indication.
- On April 13th the Board of Directors proposed a directed share issue and fully guaranteed rights issue of a total of approximately SEK 61 million to finance its clinical programs into the beginning of 2024.
|First Quarter (2022-01-01 – 2022-03-31)|
|Net revenues were TDKK 0 (0)|
|Operating loss, EBIT was TDKK -15 075 (-1 792)|
|Earnings per share was DKK –0.35 (-0.07)|
|Earnings per share, fully diluted, was DKK –0.31 (-0.06)|
|Cash: TDKK 26,352 (34,346)|
|Solidity: 65% (92%)|
Solidity: equity divided by assets.
The Board of Directors have decided that future interim reports will be published in English only.
Link to the full report